Brazil registers 202 deaths and approaches 7,000 coronavirus infections

Pharmaceutical Pfizer will conduct a study on the “immune response” to its vaccine against COVID-19 in the population of the Brazilian city of Toledo, in collaboration with a local hospital, national health authorities and academic experts, the company reported.

SIGHT: AstraZeneca vaccine: Peruvian volunteers will be followed for two years

In a statement sent to Efe, the director of Vaccine Medical Affairs for Latin America at Pfizer, Rodrigo Sini, stressed that to face the pandemic they need “multiple multi-stakeholder solutions ” and that is why the company opted to collaborate in this initiative that will last one year.

”Our association with the Moinhos de Vento Hospital, in collaboration with the National Vaccination Program, the Federal University of Paraná and the Toledo Department of Health, will allow us to gather data from the real world on the immune response of registered volunteers ”, the executive explained.

SIGHT: COVID-19 | Scientists find an antibody capable of neutralizing all variants of the coronavirus

Pfizer will vaccinate with its two-dose schedule at all residents over 12 years of age in the city, located in the south of Brazil and which has about 143,000 inhabitants, and for a year it will carry out a study on the transmission and protection against new variants of COVID-19, according to The New York Times newspaper.

The mayor of Toledo, Beto Lunitti, said in the presentation of the initiative that the town “Believe in science” and “Regrets the almost 600,000 deaths from COVID-19 in Brazil”, according to that medium.

SIGHT: The WHO officially defines persistent COVID-19 as a disease: what symptoms does it present?

The study is similar to the one that was carried out this year in another Brazilian town, Serrana, with 45,000 inhabitants, for three months with the vaccine developed by China’s SinoVac in collaboration with the Butantan Institute, an entity linked to the São Paulo state government.

RELATED VIDEO

IT MAY INTEREST YOU:

  • AstraZeneca vaccine: Peruvian volunteers will be followed for two years
  • The WHO officially defines persistent COVID-19 as a disease: what symptoms does it present?
  • CureVac Cancels Initial COVID-19 Vaccine Project
  • Merck Pill Treatment May Be New Weapon Against COVID-19, WHO Says
  • Merck Pill Treatment May Be New Weapon Against COVID-19, WHO Says
  • COVID-19 | Why do WHO experts say that the Sinopharm vaccine requires three doses?
  • Pfizer and AstraZeneca Vaccines Reduce Risk of Severe COVID-19 by 90%, Study Confirms
  • AstraZeneca Experimental Drug Reduces Severe COVID-19 Cases or Death by 67%
  • Molnupiravir | What You Should Know About MSD’s COVID-19 Pill
  • Ivermectin: How Fake Science Invented a “Miracle” Drug Against COVID-19
  • Third dose reduces the risk of severe illness from COVID-19 by 96%, according to Chilean study
  • What to answer to those who still doubt whether to get vaccinated against COVID-19
  • COVID-19 | Argentina starts vaccination with Sinopharm in children between 3 and 11 years old
  • Everything we know about COVID-19 so far
  • COVID-19 | What causes a patient in ICU to die?
  • One in eight people suffered from mental disorders in Lima due to the COVID-19 pandemic

Follow us on twitter:


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);

Leave a Reply